Single-dose Treatment of Uncomplicated Gonococcal Urethritis

Wc, Duncan; Me, McBride

doi:10.1097/00007435-198204000-00008

Sexually Transmitted Diseases

1982

DOI: 10.1097/00007435-198204000-00008

|View full text |Cite

Single-dose Treatment of Uncomplicated Gonococcal Urethritis

Duncan Wc¹,

McBride Me²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1983

1986

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to other second-generation cephalosporins, cefonicid has excellent in vitro activity against gram-positive bacteria and many aerobic gram-negative bacteria. Previous clinical studies are few, but good responses have been seen with gonococcal urethritis and community-acquired pneumonia (4,14). Cefonicid has very high serum levels after infusion and a prolonged half-life (4.8 h) allowing for once-daily dosing.…”

mentioning

confidence: 99%

Clinical trial of cefonicid for treatment of skin infections

Gremillion¹,

Winn²,

Vandenbout³

1983

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Twenty patients with skin and soft-tissue infections were treated with parenteral cefonicid. Cultures obtained in cellulitis cases from an aspirate of a leading edge of inflammation were positive in 42% of these patients. Pathogens isolated were Staphylococcus aureus (six strains), Proteus mirabilis (one strain), and Streptococcus agalactiae. Adverse effects were pain on intramuscular injection (two patients), rash (one patient), and positive Coombs test (one patient). All side effects were mild and none required discontinuing antibiotic therapy. A single treatment failure occurred in a patient with an undrained perirectal abscess. Cefonicid may be a useful drug in the treatment of skin and soft-tissue infections. The long half-life of cefonicid (4.8 h) is a valuable advantage and may facilitate patient compliance and convenience.

show abstract

mentioning

confidence: 99%

Clinical trial of cefonicid for treatment of skin infections

Gremillion¹,

Winn²,

Vandenbout³

1983

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Treatment of Uncomplicated Infections due to Neisseria gonorrhoeae

Rice¹

1986

JAMA

View full text Add to dashboard Cite

Dose ranging study of cefpimizole (U-63196E) for treatment of uncomplicated gonorrhea in men

Sandberg¹,

Pegram²,

Roddy³

et al. 1986

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We conducted a two-center dose ranging study to evaluate the efficacy, tolerance, and toxicity of cefpimizole, a new cephalosporin, in the treatment of uncomplicated gonorrhea in 96 males. Twelve patients at each center were treated intramuscularly with single doses of 1.0, 0.5, 0.2$, and 0.125 g of cefpimizole. All urethral infections were cured at the highest dose, but lower doses produced progressively decreasing cure rates of 90% (0.5 g), 83% (0.25 g), and 71% (0.125 g). Despite recent declines in the reported incidence of gonorrhea (1), consideration of new therapies for gonococcal infections is important from the standpoint of individual practitioners and public health officials. The primary impetus for investigation of new approaches to treatment has been the worldwide emergence of resistance to the antimicrobial agents commonly used for gonorrhea, including spectinomycin (4, 13). Additional problems in gonorrhea therapy include the variable efficacy of antibiotics at sites that are difficult to treat (e.g., the rectum and pharynx); coexisting chlamydial infection; and the need for improvement of antigonococcal treatment regimens in terms of tolerance, toxicity, and cost (13).A number of recently developed 3-lactam antibiotics have been evaluated as single-dose therapy of uncomplicated gonorrhea (5-9, 11, 14, 15, 18, 23). Cefpimizole (U-63196E) is another new broad-spectrum cephalosporin which demonstrates good in vitro activity against Neisseria gonorrhoeae (20). In this study we present data on a two-center, cooperative, dose ranging study of cefpimizole for the treatment of uncomplicated gonorrhea in men. Laboratory methods. Urethral specimens were obtained from all subjects by inserting a calcium alginate swab (Calgiswab; Inolex) 2 to 4 cm beyond the meatus. If indicated by the sexual history, pharyngeal and rectal specimens were collected with cotton-tipped swabs. Specimens were immediately inoculated onto modified Thayer-Martin medium and incubated at 36°C in candle extinction jars or an incubator with an atmosphere of 5% CO2. N. gonorrhoeae was identified by standard techniques of colony morphology, Gram stain, and oxidase reactions (19). Isolated colonies were subcultured onto chocolate agar medium before they were stored at -70°C in 50% horse serum diluted in Trypticase soy broth (BBL Microbiology Systems, Cockeysville, Md.). MICs of cefpimizole, penicillin G, spectinomycin, tetracycline, and cefotaxime were determined by the agar dilution technique with a gonococcal agar base containing 1% hemoglobin and 1% IsoVitaleX (BBL). Production of P-lactamase was tested by the chromogenic cephalosporin technique in MATERIALS

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Single-dose Treatment of Uncomplicated Gonococcal Urethritis

Cited by 6 publications

References 0 publications

Clinical trial of cefonicid for treatment of skin infections

Clinical trial of cefonicid for treatment of skin infections

Treatment of Uncomplicated Infections due to Neisseria gonorrhoeae

Dose ranging study of cefpimizole (U-63196E) for treatment of uncomplicated gonorrhea in men

Contact Info

Product

Resources

About